共 65 条
[1]
Garabedian T(2013)High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistance Cardiovasc Diagn Ther 3 23-37
[2]
Alam S(2013)P2Y12 receptor inhibitors in acute coronary syndromes: what is new on the horizon? Cardiol Res Pract 2013 195456-664
[3]
Oprea AD(2012)Recent advances in the pharmacogenetics of clopidogrel Hum Genet 131 653-459
[4]
Popescu WM(2011)Pharmacogenetics and clopidogrel response in patients undergoing percutaneous coronary interventions Clin Pharmacol Ther 89 455-2436
[5]
Cuisset T(2007)Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel J Thromb Haemost 5 2429-2560
[6]
Morange PE(2009)Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes Circulation 119 2553-857
[7]
Alessi MC(2009)Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy JAMA 302 849-922
[8]
Beitelshees AL(2009)Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention Eur Heart J 30 916-1774
[9]
Horenstein RB(2011)Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis JAMA 30 1765-1830
[10]
Vesely MR(2010)Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis JAMA 304 1821-206